Concepedia

John Lloyd

JL

Statistics

Publications

20

Citations

617

H-Index

16

Active since

1973

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Biocon (India)

Bristol-Myers Squibb (Sweden)

John Lloyd is an author at Bristol-Myers Squibb (United States) specializing in medicinal chemistry, pharmacology, and molecular pharmacology.

Publications per year

1973–2017

20

Publications

20

Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers

John Lloyd, Heather J. Finlay, Wayne Vacarro et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 90 citations · Full text

, , +8

Conformationally Constrained <i>ortho-</i>Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y<sub>1</sub> Antagonist

Jennifer X. Qiao, Tammy C. Wang, Réjean Ruel et al. · Journal of Medicinal Chemistry · 2013 · 70 citations · Full text

, , +17

Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography.

Dah‐Ren Hwang, W.C. Eckelman, C.J. Mathias et al. · PubMed · 1991 · 46 citations

, , +14

Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists

John Lloyd, Heather J. Finlay, Karnail S. Atwal et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 43 citations · Full text

, , +9

Biphenylsulfonamide Endothelin Antagonists:  Structure−Activity Relationships of a Series of Mono- and Disubstituted Analogues and Pharmacology of the Orally Active Endothelin Antagonist 2‘-Amino-<i>N</i>- (3,4-dimethyl-5-isoxazolyl)-4‘-(2-methylpropyl)[1,1‘-biphenyl]-2-sulfonamide (BMS-187308)

Natesan Murugesan, Zhengxiang Gu, Philip D. Stein et al. · Journal of Medicinal Chemistry · 1998 · 40 citations · Full text

, , +15

1–5 of 20